NASDAQ:SWTX SpringWorks Therapeutics (SWTX) Stock Price, News & Analysis $38.14 +1.37 (+3.73%) (As of 07/8/2024 ET) Add Compare Share Share Today's Range$36.60▼$38.3150-Day Range$36.06▼$46.8452-Week Range$18.00▼$53.92Volume412,587 shsAverage Volume717,651 shsMarket Capitalization$2.83 billionP/E RatioN/ADividend YieldN/APrice Target$68.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get SpringWorks Therapeutics alerts: Email Address SpringWorks Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside80.5% Upside$68.83 Price TargetShort InterestBearish15.17% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.45Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.62) to ($3.24) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.65 out of 5 starsMedical Sector806th out of 876 stocksBiological Products, Except Diagnostic Industry141st out of 149 stocks 3.5 Analyst's Opinion Consensus RatingSpringWorks Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSpringWorks Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about SpringWorks Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted15.17% of the outstanding shares of SpringWorks Therapeutics have been sold short.Short Interest Ratio / Days to CoverSpringWorks Therapeutics has a short interest ratio ("days to cover") of 13.9, which indicates bearish sentiment.Change versus previous monthShort interest in SpringWorks Therapeutics has recently increased by 4.07%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldSpringWorks Therapeutics does not currently pay a dividend.Dividend GrowthSpringWorks Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SWTX. Previous Next 1.9 News and Social Media Coverage News SentimentSpringWorks Therapeutics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for SpringWorks Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for SWTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added SpringWorks Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SpringWorks Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.61% of the stock of SpringWorks Therapeutics is held by insiders.Read more about SpringWorks Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for SpringWorks Therapeutics are expected to grow in the coming year, from ($4.62) to ($3.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SpringWorks Therapeutics is -7.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SpringWorks Therapeutics is -7.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSpringWorks Therapeutics has a P/B Ratio of 3.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about SpringWorks Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…Click For My #1 FREE Crypto for 2024 About SpringWorks Therapeutics Stock (NASDAQ:SWTX)SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.Read More SWTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SWTX Stock News HeadlinesJuly 7 at 2:14 AM | americanbankingnews.comBrokerages Set SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) PT at $68.83July 2, 2024 | prnewswire.comKuehn Law Encourages Investors of SpringWorks, Therapeutics Inc. to Contact Law FirmJuly 9, 2024 | Crypto 101 Media (Ad)[Urgent] Hedge Funds Expect Major Crypto MovesIn the year following Bitcoin’s last Halving event, that happened in May of 2020… Bitcoin shot up over 550%. But that’s not all… July 1, 2024 | globenewswire.comSpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PNJune 5, 2024 | globenewswire.comSpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceMay 27, 2024 | investing.comSpringWorks Therapeutics Inc (SWTX)May 23, 2024 | globenewswire.comSpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingMay 23, 2024 | benzinga.comSpringWorks Therapeutics Stock (NASDAQ:SWTX), Quotes and News SummaryJuly 9, 2024 | Crypto 101 Media (Ad)[Urgent] Hedge Funds Expect Major Crypto MovesIn the year following Bitcoin’s last Halving event, that happened in May of 2020… Bitcoin shot up over 550%. But that’s not all… May 8, 2024 | globenewswire.comSpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care ConferenceMay 6, 2024 | markets.businessinsider.comStrong Buy Rating for Springworks Therapeutics Amidst Ogsiveo’s Market Success and Robust PipelineMay 6, 2024 | msn.comSpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Q1 2024 Earnings Call TranscriptMay 5, 2024 | seekingalpha.comSpringWorks Therapeutics, Inc. 2024 Q1 - Results - Earnings Call PresentationMay 3, 2024 | finance.yahoo.comSpringWorks Therapeutics Inc (SWTX) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...May 3, 2024 | finance.yahoo.comHere's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn SituationMay 2, 2024 | markets.businessinsider.comBuy Rating for Springworks Therapeutics Amid Strong Market Performance and Promising PipelineMay 2, 2024 | investorplace.comSWTX Stock Earnings: SpringWorks Therapeutics Meets EPS, Beats Revenue for Q1 2024May 2, 2024 | washingtonpost.comSpringWorks Therapeutics: Q1 Earnings SnapshotSee More Headlines Receive SWTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SpringWorks Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today7/08/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:SWTX CUSIPN/A CIK1773427 Webwww.springworkstx.com Phone203-883-9490FaxN/AEmployees305Year Founded2017Price Target and Rating Average Stock Price Target$68.83 High Stock Price Target$75.00 Low Stock Price Target$52.00 Potential Upside/Downside+80.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($5.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-325,100,000.00 Net MarginsN/A Pretax Margin-1,281.78% Return on Equity-66.48% Return on Assets-57.28% Debt Debt-to-Equity RatioN/A Current Ratio6.85 Quick Ratio6.77 Sales & Book Value Annual Sales$5.45 million Price / Sales518.49 Cash FlowN/A Price / Cash FlowN/A Book Value$10.01 per share Price / Book3.81Miscellaneous Outstanding Shares74,090,000Free Float68,448,000Market Cap$2.83 billion OptionableOptionable Beta0.78 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Francis I. Perier Jr. (Age 64)M.B.A., Chief Financial Officer Comp: $768.24kDr. Badreddin Edris Ph.D. (Age 37)Chief Operating Officer Comp: $1.02MDr. James Cassidy M.D. (Age 64)Ph.D., Chief Medical Officer Comp: $904.25kMr. Michael P. Nofi (Age 53)Chief Accounting Officer Mr. Tai-An Lin Ph.D.Chief Scientific OfficerMs. Kim DiamondVice President of Communications & Investor RelationsMr. Herschel S. Weinstein J.D. (Age 67)General Counsel & Secretary Comp: $568.64kMr. Daniel J. Pichl (Age 40)Chief People Officer Comp: $428.51kMr. Bhavesh Ashar M.B.A. (Age 58)Chief Commercial Officer Comp: $729.62kMore ExecutivesKey CompetitorsChina Biologic ProductsNASDAQ:CBPOReplimune GroupNASDAQ:REPLAllogene TherapeuticsNASDAQ:ALLObluebird bioNASDAQ:BLUEAlloVirNASDAQ:ALVRView All CompetitorsInsiders & InstitutionsDNB Asset Management ASBought 1,617 shares on 7/5/2024Ownership: 0.015%Farallon Capital Management LLCBought 5,000 shares on 5/24/2024Ownership: 0.007%Artal Group S.A.Sold 200,000 shares on 5/17/2024Ownership: 1.910%Castleark Management LLCBought 5,300 shares on 5/17/2024Ownership: 0.106%Walleye Trading LLCBought 2,000 shares on 5/17/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions SWTX Stock Analysis - Frequently Asked Questions How have SWTX shares performed this year? SpringWorks Therapeutics' stock was trading at $36.50 at the beginning of 2024. Since then, SWTX stock has increased by 4.5% and is now trading at $38.14. View the best growth stocks for 2024 here. How were SpringWorks Therapeutics' earnings last quarter? SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) announced its quarterly earnings data on Thursday, May, 2nd. The company reported ($1.18) EPS for the quarter, missing analysts' consensus estimates of ($1.17) by $0.01. The business's quarterly revenue was up 2000.0% compared to the same quarter last year. Does SpringWorks Therapeutics have any subsidiaries? SpringWorks Therapeutics subsidiaries include SpringWorks Subsidiary 1 Inc, SpringWorks Subsidiary 2 Inc, SpringWorks Subsidiary 3 Inc, SpringWorks Subsidiary 4 Inc, SpringWorks Therapeutics LLC, and SpringWorks Therapeutics Operating Company Inc.. When did SpringWorks Therapeutics IPO? SpringWorks Therapeutics (SWTX) raised $126 million in an initial public offering on Friday, September 13th 2019. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are SpringWorks Therapeutics' major shareholders? Top institutional investors of SpringWorks Therapeutics include DNB Asset Management AS (0.02%). Insiders that own company stock include Orbimed Advisors Llc, Daniel Pichl, Julie Hambleton, Bain Capital Life Sciences Inv, Saqib Islam and L Mary Smith. View institutional ownership trends. How do I buy shares of SpringWorks Therapeutics? Shares of SWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of SpringWorks Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that SpringWorks Therapeutics investors own include Axsome Therapeutics (AXSM), Dicerna Pharmaceuticals (DRNA), Johnson & Johnson (JNJ), Albireo Pharma (ALBO), Gilead Sciences (GILD), Sunrun (RUN) and Alnylam Pharmaceuticals (ALNY). This page (NASDAQ:SWTX) was last updated on 7/9/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredYoung billionaire opens the door for millions of AmericansYou can now profit from a catalog of 11 inventions that will likely make their way into millions of U.S. house...Porter & Company | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredGrab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | SponsoredTrump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house...Wealthpin Pro | SponsoredUnexpected twist to Trump’s trialUnexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SpringWorks Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SpringWorks Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
